Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer.

Castro MA, Dal-Pizzol F, Zdanov S, Soares M, Müller CB, Lopes FM, Zanotto-Filho A, da Cruz Fernandes M, Moreira JC, Shacter E, Klamt F.

Cancer. 2010 Aug 1;116(15):3645-55. doi: 10.1002/cncr.25125.

2.

High cofilin-1 levels correlate with cisplatin resistance in lung adenocarcinomas.

Becker M, De Bastiani MA, Müller CB, Markoski MM, Castro MA, Klamt F.

Tumour Biol. 2014 Feb;35(2):1233-8. doi: 10.1007/s13277-013-1164-6. Epub 2013 Sep 10.

PMID:
24018823
3.

The expression of CFL1 and N-WASP in esophageal squamous cell carcinoma and its correlation with clinicopathological features.

Wang WS, Zhong HJ, Xiao DW, Huang X, Liao LD, Xie ZF, Xu XE, Shen ZY, Xu LY, Li EM.

Dis Esophagus. 2010 Aug;23(6):512-21. doi: 10.1111/j.1442-2050.2009.01035.x. Epub 2010 Jan 20.

PMID:
20095995
4.

Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.

Yin Z, Zhang Y, Li Y, Lv T, Liu J, Wang X.

Acta Histochem. 2012 Feb;114(2):151-8. doi: 10.1016/j.acthis.2011.04.002. Epub 2011 May 6.

PMID:
21549414
5.

Validation of cofilin-1 as a biomarker in non-small cell lung cancer: application of quantitative method in a retrospective cohort.

Müller CB, de Barros RL, Castro MA, Lopes FM, Meurer RT, Roehe A, Mazzini G, Ulbrich-Kulczynski JM, Dal-Pizzol F, Fernandes MC, Moreira JC, Xavier LL, Klamt F.

J Cancer Res Clin Oncol. 2011 Sep;137(9):1309-16. doi: 10.1007/s00432-011-1001-5. Epub 2011 Jul 8.

PMID:
21735353
6.

Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.

Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li MZ, Shi L, Zeng MS, Song LB.

Cancer. 2009 Apr 1;115(7):1507-17. doi: 10.1002/cncr.24128.

7.

Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.

Huqun, Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, Hagiwara K, Koyama N.

Cancer. 2012 Mar 15;118(6):1599-606. doi: 10.1002/cncr.26441. Epub 2011 Aug 11.

8.

Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion.

Cai S, Ye Z, Wang X, Pan Y, Weng Y, Lao S, Wei H, Li L.

J Exp Clin Cancer Res. 2015 May 15;34:48. doi: 10.1186/s13046-015-0165-2.

9.

The role of cofilin-l in vulvar squamous cell carcinoma: A marker of carcinogenesis, progression and targeted therapy.

Wu Q, Jiang Y, Cui S, Wang Y, Wu X.

Oncol Rep. 2016 May;35(5):2743-54. doi: 10.3892/or.2016.4625. Epub 2016 Feb 17.

PMID:
26936386
10.

FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.

Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ, Liu WC.

Lung Cancer. 2013 Feb;79(2):173-9. doi: 10.1016/j.lungcan.2012.10.019. Epub 2012 Nov 20.

PMID:
23177020
11.

Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.

Huang Q, Fan J, Qian X, Lv Z, Zhang X, Han J, Wu F, Chen C, Du J, Guo M, Hu G, Jin Y.

J Cancer Res Clin Oncol. 2016 Jan;142(1):263-72. doi: 10.1007/s00432-015-2040-0. Epub 2015 Aug 30.

PMID:
26319393
12.

Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.

Wu YH, Cheng YW, Chang JT, Wu TC, Chen CY, Lee H.

Cancer. 2007 Jul 1;110(1):215-23.

13.

Clinical relevance of galectin-1 expression in non-small cell lung cancer patients.

Carlini MJ, Roitman P, Nuñez M, Pallotta MG, Boggio G, Smith D, Salatino M, Joffé ED, Rabinovich GA, Puricelli LI.

Lung Cancer. 2014 Apr;84(1):73-8. doi: 10.1016/j.lungcan.2014.01.016. Epub 2014 Jan 28.

PMID:
24560493
14.

Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition.

Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ, Chen JF, Zhang EB, De W, Wang ZX.

Mol Cancer. 2014 Mar 21;13:68. doi: 10.1186/1476-4598-13-68.

15.

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA.

Lung Cancer. 2015 Aug;89(2):181-8. doi: 10.1016/j.lungcan.2015.05.007. Epub 2015 May 18.

PMID:
26024796
16.

Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.

17.

The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer.

Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W.

BMC Cancer. 2013 Oct 8;13:464. doi: 10.1186/1471-2407-13-464.

18.

Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.

Malentacchi F, Simi L, Nannelli C, Andreani M, Janni A, Pastorekova S, Orlando C.

Lung Cancer. 2009 Jun;64(3):271-6. doi: 10.1016/j.lungcan.2008.10.001. Epub 2008 Nov 20.

PMID:
19022520
19.

A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer.

Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, Hsu PY, Wu G, Lin CH, Chang GC, Li KC, Yang PC.

Clin Cancer Res. 2009 Dec 1;15(23):7309-15. doi: 10.1158/1078-0432.CCR-09-1572. Epub 2009 Nov 17.

20.

Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.

Zhang Z, Ma J, Li N, Sun N, Wang C.

Ann Thorac Surg. 2006 Jul;82(1):243-8.

PMID:
16798222

Supplemental Content

Support Center